XML 54 R19.htm IDEA: XBRL DOCUMENT v3.25.2
Stock Option Plan
 6 Months Ended
Jun. 30, 2025
Share-Based Payment Arrangement [Abstract]  
Stock Option Plan Stock Option Plan
In 2010, the Company adopted the 2010 Equity Incentive Plan (the “2010 Plan”), which provides for the grant of restricted stock awards, stock options, and other share-based awards to employees, consultants, and directors. In November 2020, the Board extended the term of the 2010 Plan to July 1, 2021. In 2021, the Company adopted the 2020 Equity Incentive Plan (the “2020 Plan”), which provides for the grant of restricted stock awards, incentive and non-statutory stock options, and other share-based awards to employees, consultants, and directors. In June 2023, the 2020 Plan was amended, as approved by shareholders, to increase the shares of common stock reserved for issuance under the plan by 10,000 shares. As of June 30, 2025, there is an aggregate of 63,497 shares of common stock reserved for issuance under the 2020 Plan. All options granted to date have a ten year contractual life and vesting terms of four years. In general, vested options expire if not exercised 90 days after termination of service. A total of 55,408 shares of common stock remained available for future issuance under the 2020 Plan as of August 7, 2025. Forfeitures are accounted for as they occur.
Stock-based compensation expense recognized in selling, general, and administrative, and research and development are as follows:
Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
Options$14,022 $362,748 $568,681 $1,040,231 
Restricted stock— 119,052 — 287,956 
Stock options - modified options— — — 169 
Profit interest units(1)— 31,226 — 62,452 
    Total$14,022 $513,026 $568,681 $1,390,808 
__________________
(1) Profit interest is related to Levo which has been dissolved as an entity. See Note 18.
The following is a summary of the stock option activity under the 2010 Plan for the six months ended June 30, 2025:
SharesWeighted-
Average
Exercise
Price per
Share($)		Weighted-
Average
Remaining
Contractual
Term
(Years)		Aggregate Intrinsic Value($)
Outstanding - December 31, 20241,916 1,033.97 2.54— 
Granted— — — — 
Exercised— — — — 
Forfeited— — — — 
Expired/Cancelled— — — — 
Outstanding - June 30, 20251,916 1,034.00 2.05— 
Options Exercisable at June 30, 20251,916 1,033.60 2.05— 
Options Vested at June 30, 2025
1,916 1,033.60 2.05— 
The weighted-average grant-date fair value of options granted during the six months ended June 30, 2025 was zero.
The following is a summary of the stock option activity under the 2020 Plan for the six months ended June 30, 2025:
SharesWeighted-
Average
Exercise
Price per
Share ($)		Weighted-
Average
Remaining
Contractual
Term
(Years)		Aggregate Intrinsic Value($)
Outstanding - December 31, 20244,743 3,874.89 6.68— 
Granted— — — — 
Exercised— — — — 
Forfeited— — — — 
Expired/Cancelled(10)2,708.00 — — 
Outstanding - June 30, 20254,733 3,877.35 5.95— 
Options Exercisable at June 30, 20253,699 4,993.33 6.20— 
Options Vested at June 30, 2025
3,699 4,993.33 6.20— 

The weighted-average grant-date fair value of options granted during the six months ended June 30, 2025 was zero.
During the year ended December 31, 2021, 4,100 options were modified to lower the exercise price by $240.00 per share, which resulted in $246,000 of incremental compensation cost to be recognized over the remaining vesting period. The amount of additional compensation expense for the three and six months ended June 30, 2024, was $169.
Other Information:
Six Months Ended
June 30,		 
20252024
Amount received from option exercised$— $— 
June 30, 2025Weighted average remaining recognition period
Total unrecognized options compensation costs$24,482  1.47
No amounts relating to the 2010 Plan or 2020 Plan have been capitalized. Compensation cost is recognized over the requisite service period based on the fair value of the options.
The Company did not have any nonvested restricted stock units as of the six months ended June 30, 2025.
As of June 30, 2025, there was zero of total unrecognized compensation cost related to nonvested restricted stock.